Extending Survival with Chemotherapy in Metastatic Breast Cancer

Rakesh K. Jain, Antiangiogenic Therapy for Cancer: Current and Emerging Concepts Oncology. ,vol. 19, pp. 7- 15 ,(2005)

J.-M. Nabholtz, H. J. Senn, W. R. Bezwoda, D. Melnychuk, L. Deschênes, J. Douma, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W.R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P.S.G.J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy Journal of Clinical Oncology. ,vol. 17, pp. 1413- 1424 ,(1999) , 10.1200/JCO.1999.17.5.1413

Jacek Jassem, Tadeusz Pieńkowski, Anna Płuzańska, Svetislav Jelic, Vera Gorbunova, Zrinka Mrsic-Krmpotic, Juris Berzins, Tomas Nagykalnai, Nelly Wigler, Josette Renard, Stephane Munier, Catherine Weil, Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial Journal of Clinical Oncology. ,vol. 19, pp. 1707- 1715 ,(2001) , 10.1200/JCO.2001.19.6.1707

James F. Bishop, Joanna Dewar, Guy C. Toner, Jennifer Smith, Martin H.N. Tattersall, Ian N. Olver, Stephen Ackland, Ian Kennedy, David Goldstein, Howard Gurney, Euan Walpole, John Levi, Jennifer Stephenson, Renzo Canetta, Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology. ,vol. 17, pp. 2355- 2364 ,(1999) , 10.1200/JCO.1999.17.8.2355

Joanne L. Blum, Stephen E. Jones, Aman U. Buzdar, Patricia Mucci LoRusso, Irene Kuter, Charles Vogel, Bruno Osterwalder, Hans-Ulrich Burger, Cheryl Stoner Brown, Tom Griffin, Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 485- 493 ,(1999) , 10.1200/JCO.1999.17.2.485

R. Paridaens, L. Biganzoli, P. Bruning, J.G. M. Klijn, T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, A. Awada, J. Wildiers, M. Piccart, , Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer : a European organization for research and treatment of cancer randomized study with cross-over Journal of Clinical Oncology. ,vol. 18, pp. 724- 733 ,(2000) , 10.1200/JCO.2000.18.4.724

K Jin Kim, Bing Li, Jane Winer, Mark Armanini, Nancy Gillett, Heidi S Phillips, Napoleone Ferrara, None, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature. ,vol. 362, pp. 841- 844 ,(1993) , 10.1038/362841A0

P. Reichardt, G. von Minckwitz, H.J. Lück, P.C. Thuss-Patience, W. Jonat, H. Kölbl, D. Kiebak, W. Kuhn, F. Floemer, S. Frings, Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial European Journal of Cancer. ,vol. 37, ,(2001) , 10.1016/S0959-8049(01)81191-6

J Bonneterre, H Roché, A Monnier, J P Guastalla, M Namer, P Fargeot, S Assadourian, Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure British Journal of Cancer. ,vol. 87, pp. 1210- 1215 ,(2002) , 10.1038/SJ.BJC.6600645

M. Bontenbal, J.J. Braun, G.J. Creemers, A.C. de Boer, J.Th.P. Janssen, M.B.L. Leys, K.L.C. Schothorst, P.I.M. Schmitz, J.J. Bokma, C. Seynaeve, 671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC) Ejc Supplements. ,vol. 1, ,(2003) , 10.1016/S1359-6349(03)90702-6